Episodes (Page 2)
✨
Cancer Research UK's commercial arm builds companies from lab discoveries.
Neil Jones
Phil Masterson
✨
Patients sought generic cystic fibrosis treatment in Bangladesh.
Gayle Pledger
Josh Lottering
Wilna Lottering
✨
Challenges in adopting innovative medical devices post-approval.
Mark Saxton
✨
Rx-to-OTC switch is a reliable innovation in self-care.
Christelle Anquez-Traxler
✨
ZS survey reveals rapid patient adoption of AI healthcare tools.
Bhargav Mantha
Jon Roffman
✨
Potential differences in MFN drug pricing for mid-size companies.
✨
Concerns over US tariffs on generic drugs from domestic and foreign sources.
✨
Sophie McGrath discusses healthtech and biopharma trends from a legal perspective.
Sophie McGrath
✨
Analysis of Heidi Overton's prospects for FDA commissioner confirmation.
✨
EndoCyclic Therapeutics develops a precision peptide platform for endometriosis.
Tanya Petrossian
✨
Mid-cap biopharmas are increasingly acquiring to extend growth beyond initial successes.
Jessica Merrill
✨
Consumer health is exploring products to support GLP-1 users.
Beverley Law
Martina Gripp
✨
PDUFA VIII will collect less revenue, impacting FDA funding.
✨
Biotech leaders navigate disciplined growth and global shifts.
Claire Riches
Ross Pettit
✨
Annexon transitions to commercialization for GBS and GA treatments.
Doug Love
✨
Nationalism impacts regulatory processes, seen in potential mergers.
✨
AI and simulation in drug discovery are examined honestly.
Krishna Bulusu
✨
CE Mark for vision-restoring implant and AI chatbot regulations discussed.
✨
China's role in global clinical development is evolving.
✨
Dave Wallace discusses 16 years covering the off-patent drug industry.